Key result
Heparin increases fracture risk, whereas LMWHs and DOACs appear safer for bone health.
Answers are grounded in this paper and cite their sources.
Anticoagulant agents are widely used in the treatment of thromboembolic events and in stroke prevention. Data about their effects on bone tissue are in some cases limited or inconsistent (oral anti-vitamin K agents), and in others are sufficiently strong (heparins) to suggest caution in their use in subjects at risk of osteoporosis. This review analyses the effects of this group of drugs on bone metabolism, on bone mineral density, and on fragility fractures. A literature search strategy was developed by an experienced team of specialists by consulting the MEDLINE platform, including published papers and reviews updated to March 2019. Literature supports a detrimental effect of heparin on bone, with an increase in fracture rate. Low molecular weight heparins (LMWHs) seem to be safer than heparin. Although anti-vitamin K agents (VKAs) have a significant impact on bone metabolism, and in particular, on osteocalcin, data on bone mineral density (BMD) and fractures are contrasting. To date, the new direct oral anticoagulants (DOACs) are found to safe for bone health.
No takes yet. Share an insight, caveat, or question.
Signorelli et al. (2019) conducted a review in Osteoporosis and thromboembolic events. Anticoagulant agents (heparins, LMWHs, VKAs, DOACs) was evaluated on Bone metabolism, bone mineral density, and fragility fractures. Heparin increases fracture rates, whereas LMWHs and DOACs appear safer for bone health, and VKAs show contrasting data on BMD and fractures.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: